Recce Pharmaceuticals Ltd
ASX:RCE

Watchlist Manager
Recce Pharmaceuticals Ltd Logo
Recce Pharmaceuticals Ltd
ASX:RCE
Watchlist
Price: 0.455 AUD -5.21% Market Closed
Market Cap: 105.5m AUD
Have any thoughts about
Recce Pharmaceuticals Ltd?
Write Note

EV/EBIT
Enterprise Value to EBIT

-6
Current
-11
Median
17
Industry
Higher than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-6
=
Enterprise Value
101.6m AUD
/
EBIT
-16.8m AUD
All Countries
Close
EBIT Growth EV/EBIT to Growth
AU
Recce Pharmaceuticals Ltd
ASX:RCE
Average EV/EBIT: 2 011.8
Negative Multiple: -6
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
53
211%
0.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
675%
26.2
DK
Novo Nordisk A/S
CSE:NOVO B
28.3
83%
0.3
US
Johnson & Johnson
NYSE:JNJ
15.1
28%
0.5
US
Merck & Co Inc
NYSE:MRK
12.6
675%
0
CH
Roche Holding AG
SIX:ROG
11.9
28%
0.4
UK
AstraZeneca PLC
LSE:AZN
254.1
131%
1.9
CH
Novartis AG
SIX:NOVN
13.3
58%
0.2
US
Pfizer Inc
NYSE:PFE
15.9
68%
0.2

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-7.7
2-Years Forward
EV/EBIT
-1.5
3-Years Forward
EV/EBIT
N/A

See Also

Discover More